Literature DB >> 29030294

Type I interferon pathway activation in COPA syndrome.

Stefano Volpi1, Jessica Tsui2, Marcello Mariani3, Claudia Pastorino1, Roberta Caorsi3, Oliviero Sacco4, Angelo Ravelli3, Anthony K Shum2, Marco Gattorno1, Paolo Picco5.   

Abstract

Mutations of the COPA gene cause an immune dysregulatory disease characterised by polyarticular arthritis and progressive interstitial lung disease with pulmonary haemorrhages. We report the case of a young girl that presented at age 3 with polyarticular arthritis, chronic cough and high titer rheumatoid factor. Radiologic imaging showed interstitial lung disease with tree-in-a-bud nodules and air-filled cysts. Targeted genetic analysis of COPA gene showed the reported c.698G>A mutation. The patient was lost to follow up for 3years during which therapy was discontinued with the development of joint damage and deformities. Analysis of peripheral blood showed activation of type 1 interferon pathway, which was also confirmed in 4 previously reported COPA patients. Our observations underline the importance of early treatment in COPA disease to avoid loss of joint function. Furthermore, our results suggest a role for type 1 interferon in disease pathogenesis opening the possibility for targeted therapeutic approaches.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  Autoinflammatory diseases; COPA syndrome; Type 1 interferonopathy

Mesh:

Substances:

Year:  2017        PMID: 29030294     DOI: 10.1016/j.clim.2017.10.001

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  27 in total

Review 1.  Toward a better understanding of type I interferonopathies: a brief summary, update and beyond.

Authors:  Zhong-Xun Yu; Hong-Mei Song
Journal:  World J Pediatr       Date:  2019-08-03       Impact factor: 2.764

Review 2.  An Update on Autoinflammatory Diseases: Interferonopathies.

Authors:  Sophia Davidson; Annemarie Steiner; Cassandra R Harapas; Seth L Masters
Journal:  Curr Rheumatol Rep       Date:  2018-05-30       Impact factor: 4.592

Review 3.  Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach.

Authors:  Peter A Nigrovic; Pui Y Lee; Hal M Hoffman
Journal:  J Allergy Clin Immunol       Date:  2020-11       Impact factor: 10.793

Review 4.  Baricitinib in therapy of COPA syndrome in a 15-year-old girl.

Authors:  Sophia Krutzke; Christoph Rietschel; Gerd Horneff
Journal:  Eur J Rheumatol       Date:  2019-08-20

Review 5.  Coatopathies: Genetic Disorders of Protein Coats.

Authors:  Esteban C Dell'Angelica; Juan S Bonifacino
Journal:  Annu Rev Cell Dev Biol       Date:  2019-08-09       Impact factor: 13.827

Review 6.  Intracellular Sensing of DNA in Autoinflammation and Autoimmunity.

Authors:  Susan MacLauchlan; Katherine A Fitzgerald; Ellen M Gravallese
Journal:  Arthritis Rheumatol       Date:  2022-09-06       Impact factor: 15.483

7.  A Defect in Thymic Tolerance Causes T Cell-Mediated Autoimmunity in a Murine Model of COPA Syndrome.

Authors:  Zimu Deng; Christopher S Law; Frances O Ho; Kristin M Wang; Kirk D Jones; Jeoung-Sook Shin; Anthony K Shum
Journal:  J Immunol       Date:  2020-03-20       Impact factor: 5.422

Review 8.  STING-Mediated Lung Inflammation and Beyond.

Authors:  Marie-Louise Frémond; Yanick J Crow
Journal:  J Clin Immunol       Date:  2021-02-02       Impact factor: 8.317

9.  STING-Associated Vasculopathy with Onset in Infancy in Three Children with New Clinical Aspect and Unsatisfactory Therapeutic Responses to Tofacitinib.

Authors:  Xiaolei Tang; Hui Xu; Chunju Zhou; Yun Peng; Hui Liu; Jinrong Liu; Huimin Li; Haiming Yang; Shunying Zhao
Journal:  J Clin Immunol       Date:  2019-11-08       Impact factor: 8.542

Review 10.  Childhood rare lung disease in the 21st century: "-omics" technology advances accelerating discovery.

Authors:  Timothy J Vece; Jennifer A Wambach; James S Hagood
Journal:  Pediatr Pulmonol       Date:  2020-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.